159 related articles for article (PubMed ID: 30482666)
1. Association between venous thromboembolism events and fibrates: A comparative study.
Dolladille C; Humbert X; Faucon M; Tournilhac C; Sassier M; Fedrizzi S; Milliez P; Lelong-Boulouard V; Coquerel A; Puddu PE; Parienti JJ; Alexandre J
Therapie; 2019 Jun; 74(3):421-430. PubMed ID: 30482666
[TBL] [Abstract][Full Text] [Related]
2. [Fibrates and risk of venous thromboembolism: Case/no-case study in French pharmacovigilance database].
Humbert X; Dolladille C; Sassier M; Valnet-Rabier MB; Vial T; Guitton E; Page A; Sole E; Auriche P; Coquerel A; Alexandre J; Fedrizzi S
Therapie; 2017 Dec; 72(6):677-682. PubMed ID: 28941579
[TBL] [Abstract][Full Text] [Related]
3. Risk of diabetes with fibrates and statins: a pharmacoepidemiological study in VigiBase
Montastruc F; Benevent J; Rousseau V; Durrieu G; Sommet A; Montastruc JL
Fundam Clin Pharmacol; 2019 Feb; 33(1):108-112. PubMed ID: 30098074
[TBL] [Abstract][Full Text] [Related]
4. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
[TBL] [Abstract][Full Text] [Related]
5. A pharmacovigilance study of the association between antipsychotic drugs and venous thromboembolism based on Food and Drug Administration Adverse Event Reporting System data.
Yan Y; Wang L; Yuan Y; Xu J; Chen Y; Wu B
Expert Opin Drug Saf; 2024 Jun; 23(6):771-776. PubMed ID: 37615268
[TBL] [Abstract][Full Text] [Related]
6. Lipid parameters, lipid lowering drugs and the risk of venous thromboembolism.
Delluc A; Malécot JM; Kerspern H; Nowak E; Carre JL; Mottier D; Le Gal G; Lacut K
Atherosclerosis; 2012 Jan; 220(1):184-8. PubMed ID: 22035572
[TBL] [Abstract][Full Text] [Related]
7. [Effects of Fibrates on Risk of Development of Diabetic Retinopathy in Japanese Working Age Patients with Type 2 Diabetes and Dyslipidemia: a Retrospective Cohort Study].
Akimoto H; Takahashi Y; Asai S
Yakugaku Zasshi; 2021; 141(5):761-769. PubMed ID: 33952760
[TBL] [Abstract][Full Text] [Related]
8. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.
Amend KL; Landon J; Thyagarajan V; Niemcryk S; McAfee A
Ann Pharmacother; 2011 Oct; 45(10):1230-9. PubMed ID: 21917557
[TBL] [Abstract][Full Text] [Related]
9. Derivation and validation of a clinical prediction model for risks of venous thromboembolism in diabetic and general populations.
Lin CC; Chen CC; Li CI; Liu CS; Lin WY; Lin CH; Yang SY; Li TC
Medicine (Baltimore); 2021 Oct; 100(39):e27367. PubMed ID: 34596150
[TBL] [Abstract][Full Text] [Related]
10. Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia?
Lacut K; Le Gal G; Abalain JH; Mottier D; Oger E
Thromb Res; 2008; 122(3):314-9. PubMed ID: 18048086
[TBL] [Abstract][Full Text] [Related]
11. Statins, fibrates, and venous thromboembolism: a meta-analysis.
Squizzato A; Galli M; Romualdi E; Dentali F; Kamphuisen PW; Guasti L; Venco A; Ageno W
Eur Heart J; 2010 May; 31(10):1248-56. PubMed ID: 20031958
[TBL] [Abstract][Full Text] [Related]
12. Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations.
Hamilton-Craig I; Kostner KM; Woodhouse S; Colquhoun D
Int J Evid Based Healthc; 2012 Sep; 10(3):181-90. PubMed ID: 22925614
[TBL] [Abstract][Full Text] [Related]
13. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization.
Holmqvist ME; Neovius M; Eriksson J; Mantel Ä; Wållberg-Jonsson S; Jacobsson LT; Askling J
JAMA; 2012 Oct; 308(13):1350-6. PubMed ID: 23032551
[TBL] [Abstract][Full Text] [Related]
14. Is diabetes mellitus an independent risk factor for venous thromboembolism?: a population-based case-control study.
Heit JA; Leibson CL; Ashrani AA; Petterson TM; Bailey KR; Melton LJ
Arterioscler Thromb Vasc Biol; 2009 Sep; 29(9):1399-405. PubMed ID: 19542020
[TBL] [Abstract][Full Text] [Related]
15. Retrospective administrative database study of the time period of venous thromboembolism risk during and following hospitalization for major orthopedic or abdominal surgery in real-world US patients.
Amin AN; Lenhart G; Princic N; Lin J; Thompson S; Johnston S
Hosp Pract (1995); 2011 Apr; 39(2):7-17. PubMed ID: 21576893
[TBL] [Abstract][Full Text] [Related]
16. Plasma homocysteine and the risk of venous thromboembolism: insights from the FIELD study.
Herrmann M; Whiting MJ; Veillard AS; Ehnholm C; Sullivan DR; Keech AC;
Clin Chem Lab Med; 2012 Dec; 50(12):2213-9. PubMed ID: 23093273
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of and Factors Associated With the Prescription of Fibrates Among Patients Receiving Lipid-Lowering Drugs in Germany.
Jacob L; Greiner RA; Luedde M; Kostev K
J Cardiovasc Pharmacol; 2021 Dec; 78(6):885-890. PubMed ID: 34654787
[TBL] [Abstract][Full Text] [Related]
18. Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case-control study.
Ashrani AA; Barsoum MK; Crusan DJ; Petterson TM; Bailey KR; Heit JA
Thromb Res; 2015 Jun; 135(6):1110-6. PubMed ID: 25891841
[TBL] [Abstract][Full Text] [Related]
19. Antipsychotic drug use and the risk of venous thromboembolism in elderly patients with dementia.
Schmedt N; Garbe E
J Clin Psychopharmacol; 2013 Dec; 33(6):753-8. PubMed ID: 24052055
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab Use and the Risk of Arterial and Venous Thromboembolism in Patients with High-Grade Gliomas: A Nested Case-Control Study.
Lee I; Adimadhyam S; Nutescu EA; Zhou J; Asfaw AA; Sweiss KI; Patel PR; Calip GS
Pharmacotherapy; 2019 Sep; 39(9):921-928. PubMed ID: 31332810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
